ALS
ALS is a global leader in providing laboratory testing, inspection, certification and verification solutions.
- Est. revenue
- $1B–$1000B
- Employees
- 13,638
Funding & revenue at ALS
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Estimated annual revenue
$1B–$1000B
Modeled range, not company-reported
Publicly traded
ALS, ALQ
IPO Jul 1952
Growth signals
How fast ALS is adding people, roles, and audience.
Employees
13,638
Reported band 10001+
Open roles
265
+0.1% year over year
LinkedIn followers
354K
+38.9% year over year
Headcount change
- MoM
- +0.2%
- +22 people
- QoQ
- +1.1%
- +150 people
- 6mo
- +2.8%
- +371 people
- YoY
- +6.3%
- +808 people
- 2yr
- +12.9%
- +1,561 people
Team composition
Where ALS concentrates its people — a read on which function a fractional leader would plug into.
By function
- Research4,14030%
- Operations1,76613%
- Engineering1,0978%
- Business Development9647%
- Information Technology6985%
- Administrative6195%
- Quality Assurance4603%
- Sales4373%
By region
- Australia1,713
- United States1,343
- Canada1,299
- United Kingdom1,237
- Brazil1,199
- England, United Kingdom1,088
Inside ALS
What the business focuses on, where it operates, and how employees rate it.
Specialties
Categories
Markets
Offices
- 10450 Stancliff Rd., Houston, Texas, 77099, US
ALS in the news
Recent coverage picked up alongside the firmographic refresh.
- Enrollment complete in Phase 2b trial of add-on therapy for adults with ALS
Sep 2026
- EverythingALS and Vision 2030 Announce Expanded International Scientific Advisory Board to Support ALS Research Collaboration
Sep 2026
- Macquarie Group Becomes Substantial Holder in ALS Limited with 5.03% Voting Power
Sep 2026
- Macquarie Group Acquires 5.03% Voting Stake, Becomes Major Shareholder in ALS Limited (ASX:ALQ)
Sep 2026
- BlackRock Inc. Lodges Substantial Shareholder Notice for ALS Limited
Sep 2026
- PhenoNet, Inc. Completes Recruitment and Randomization in Phase IIb Clinical Trial Evaluating PHENOGENE-1A for Amyotrophic Lateral Sclerosis (ALS)
Sep 2026
Jobs
0No open roles right now — view past roles below
Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed September 17, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent ALS, you can claim this page to manage and enhance it.